[2]. This can be explained by the presence of systemic micrometastatic disease. Breast cancer follow-up for the purpose of early detection of local or metastatic recurrence is predominantly based on clinical examination and mammography, and previously suggested tumor markers, such as CA 15.3, CA 27.29 and carcinoembryonic antigen (CEA), are not recommended in the routine follow-up after initial treatment [3]. This evidence concerns the gene CEACAM5 and neoplasm.